An AI Awakening With Profluent Bio's Hilary Eaton, Ph.D.

Hilary Eaton, Ph.D. was a self-described AI skeptic, particularly as it relates to using the tool in drug discovery. Then, a series of professional and deeply personal life events and medical discoveries put her in a position to confront that skepticism head-on. Today, she's Chief Business Officer at ProFluent Bio, a company that's committed to democratizing access to open-source AI gene editing tools that are custom-built for pharmaceutical development. On this episode of the Business of Biotech, Dr. Eaton shares her story and makes a pragmatic case for the transformative value of AI to biotech builders. Whether your bullish or bearish about the intersection of advanced therapeutic development and artificial intelligence, this one's a must-listen.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: / matthewpillar
---
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:
Apple - podcasts.apple...
Spotify - open.spotify.c...
RUclips - • The Business Of Biotec...